Research
Hormonal
Consumption of n-3 polyunsaturated fatty acids (PUFAs), specifically EPA and DHA, provides cardioprotection by reducing inflammation, preventing microthrombus formation, and improving survival post-ischemia.
Increase your intake of n-3 PUFAs found in fish and marine animals (EPA and DHA) or plant sources like flaxseed (ALA). These fats help reduce inflammation, prevent blood clots, and protect the heart during stress, unlike diets high in n-6 PUFAs which may increase heart attack risk.
GoodSupportsHIGH confidence
Since n-3 PUFAs are less likely to create vessel lumen closure, such as atherosclerosis, the myocardium is less likely to be subjected to an ischemic event and in turn scar formation. This would prevent an overall decrease in cardiac output [2-5].
Why this rating
Strong evidence from human and animal models, though some controversy exists regarding specific sources like ALA.
Source
Trans Fatty Acids and Cardiovascular Disease
Dariush Mozaffarian et al. · New England Journal of Medicine · 2006
DOI 10.1056/nejmra054035
narrative_reviewCited 1,756×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Consumption of industrial trans fatty acids (iTFA) increases the risk of cardiovascular disease and myocardial infarction through pro-inflammatory actions and atherosclerosis development, whereas ruminant trans fatty acids (rTFA) may possess anti-atherogenic properties.Good
- n-6 fatty acids, specifically arachidonic acid (AA), increase the susceptibility of cardiomyocytes to apoptosis and arrhythmias during ischemia/reperfusion injury through Ca2+/Na+ mediated actions and increased inflammatory biomarkers.Moderate
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →